Reference : Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal ...
Scientific journals : Article
Human health sciences : Rheumatology
http://hdl.handle.net/2268/94592
Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis
English
Kaye, O. [ > > ]
Palazzo, E. [ > > ]
Grossin, M. [ > > ]
Bourgeois, P. [ > > ]
Kahn, M. F. [ > > ]
Malaise, Michel mailto [Université de Liège - ULg > Département des sciences cliniques > Rhumatologie >]
1995
British Journal of Rheumatology
Oxford University Press
34
7
642-644
Yes (verified by ORBi)
International
0263-7103
Oxford
United Kingdom
[en] Adrenal Cortex Hormones ; Methotrexate ; Musculoskeletal Diseases
[en] Extrapulmonary sarcoidosis, and particularly the presence of musculoskeletal
complications of the disease, may require chronic corticosteroid therapy. In five
patients with biopsy-proven sarcoidosis and presenting recalcitrant forms of the
disease, we introduced low-dose oral methotrexate (MTX) [10 mg/week (7.5-15)] for
30 months (16-34) to control the clinical and biological symptoms as well as to
try to reduce the intolerated steroid posology. Beneficial effects were observed
within 8-12 weeks in all patients, which allowed a reduction of 59% (35-75) of
the corticosteroid posology, and maintained with a follow-up of 3 yr in 4/5
patients. No significant toxicity was observed. MTX appears to be an efficient,
safe and corticosteroid-sparing therapeutic agent for the treatment of
recalcitrant musculoskeletal manifestations of sarcoidosis.
Researchers ; Professionals
http://hdl.handle.net/2268/94592

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Malaise_1995_BrJRheumatol_642-644.pdfPublisher postprint704.48 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.